Orserdu (Elacestrant)

Save 25% on brand name Orserdu from Europe.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Orderdu originating from Europe is manufactured at the following site(s):Stemline Therapeutics B.V. Basisweg 10 1043 AP Amsterdam The NetherlandsBerlin Chemie AG Glienicker Weg 125 12489 Berlin Germany

Information about Orserdu (Elacestrant)

Orserdu (generic name elacestrant) is an oral medication used in the treatment of hormone receptor-positive (HR-positive), HER2-negative breast cancer. Specifically, Orserdu is indicated for patients with locally advanced or metastatic breast cancer who have progressed on or after prior endocrine therapy. It is a selective estrogen receptor degrader (SERD) that works by targeting and degrading the estrogen receptor (ER), which is a key driver of growth in many types of breast cancer.

Product Highlights

• Orserdu is indicated for the treatment of locally advanced or metastatic estrogen receptor-positive (HR-positive) breast cancer in patients whose disease has progressed on or after endocrine therapy. These patients typically have tumors that express estrogen receptors, which are stimulated by the hormone estrogen to promote cancer cell growth.
• It is specifically used in patients who have failed prior endocrine therapy, including aromatase inhibitors or SERMs (selective estrogen receptor modulators).

Key Ingredient

• Elacestrant

Key Benefits of Orserdu (Elacestrant)

• Orserdu provides an option for patients whose breast cancer has progressed despite other forms of endocrine therapy. It helps to degrade the estrogen receptor and block estrogen-driven tumor growth.
• Orserdu is taken as a convenient oral tablet, offering an alternative to intravenous or injection-based therapies, which can be burdensome for patients.
• By specifically targeting the estrogen receptor, Orserdu aims to directly interfere with the pathways that promote cancer cell proliferation, making it a targeted therapy with fewer off-target effects compared to traditional chemotherapies.
• Clinical trials have shown that Orserdu can significantly improve progression-free survival in patients with metastatic or locally advanced HR-positive breast cancer who have failed previous endocrine treatments.

Direction of Use

• The recommended dose of Orserdu is 400 mg (one tablet) taken once daily. This dose should be taken at the same time each day for optimal efficacy.
• Orserdu tablets should be taken orally with food, and they should be swallowed whole without chewing, crushing, or breaking them.
• For maximum benefit, it is important to take Orserdu consistently every day, at the same time each day, to maintain steady drug levels in the body.
• If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. If you miss a dose, skip it and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one.

Safety Concerns

• Elacestrant may affect liver function. Liver enzymes should be monitored regularly, especially in patients with pre-existing liver conditions. Patients with severe liver impairment may require dose modifications.
• Orserdu may cause a prolongation of the QT interval on an electrocardiogram (ECG), which can increase the risk of serious heart arrhythmias. Baseline ECG monitoring is recommended.
• Some patients may experience gastrointestinal issues such as nausea, vomiting, diarrhea, or abdominal discomfort. These side effects are typically mild, but they should be monitored and managed accordingly.
• Orserdu is classified as Pregnancy Category D, meaning it may harm a developing fetus. Women who are pregnant or planning to become pregnant should avoid Orserdu. Effective contraception should be used during treatment and for some time after discontinuing the medication.
• It is unknown whether Orserdu is excreted in breast milk. Due to potential risks to a nursing infant, breastfeeding is not recommended during treatment with Orserdu.
• Orserdu may interact with other medications, particularly those that affect liver enzymes such as CYP3A4 inhibitors or inducers. A healthcare provider should be notified of all other medications, including over-the-counter drugs, vitamins, and supplements.

Avoid Orserdu (Elacestrant) If

• Orserdu should not be used during pregnancy as it may harm the fetus. Women of reproductive age should use effective contraception while taking this medication and for some time after stopping it.
• Orserdu should be avoided in individuals who have a known allergy to elacestrant or any of the other ingredients in the formulation.
• Orserdu is contraindicated in patients with severe liver impairment (e.g., cirrhosis or active liver disease). Liver function should be assessed before starting therapy.
• Women who are breastfeeding should avoid Orserdu as it is unknown whether the drug passes into breast milk and could affect the infant.
• Patients with a history of QT prolongation, arrhythmias, or severe heart conditions should avoid Orserdu or use it with extreme caution under close medical supervision.